3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
8
Tumor-Agnostic
3
Thoracic
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
pembrolizumab
28
Docetaxel
21
Gemcitabine
19
Nivolumab
14
Paclitaxel
13
Prednisone
11
Leuprolide
11
pazopanib
10
Radiotherapy
10
Cisplatin
10
Sunitinib
9
Sorafenib
9
Ipilimumab
8
Blood Specimen Collection
8
Bevacizumab
8
avelumab
7
Therapeutics
7
Thalidomide
7
Cyclophosphamide
7
Carboplatin
7
atezolizumab
6
Standard of Care
6
Radiation
6
Mitomycin
6
Interleukin-2
6
Cetuximab
6
Axitinib
6
padeliporfin
5
cemiplimab
5
Radiosurgery
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Folfox protocol
×
Genitourinary
×
Clear all
NCT02009449
2024-11-15
IVY
Eli Lilly and Company
Phase 1
Completed
353 enrolled